{"generic":"Chlorothiazide Sodium","drugs":["Chlorothiazide Sodium","Diuril Sodium","Sodium Diuril"],"mono":{"0":{"id":"923284-s-0","title":"Generic Names","mono":"Chlorothiazide Sodium"},"1":{"id":"923284-s-1","title":"Dosing and Indications","sub":[{"id":"923284-s-1-4","title":"Adult Dosing","mono":"<ul><li>switch to oral therapy whenever possible using the same dose as IV<\/li><li><b>Edema:<\/b> 500 to 1000 mg IV once or twice daily; may also give intermittently (alternate days or 3 to 5 days per week)<\/li><\/ul>"},{"id":"923284-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy of chlorothiazide sodium have not been established in pediatric patients "},{"id":"923284-s-1-6","title":"Dose Adjustments","mono":"<b>geriatric:<\/b> start at low end of dosing range "},{"id":"923284-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Edema<br\/>"}]},"3":{"id":"923284-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923284-s-3-9","title":"Contraindications","mono":"<ul><li>anuria<\/li><li>hypersensitivity to any component of this product or to other sulfonamide-derived drugs<\/li><\/ul>"},{"id":"923284-s-3-10","title":"Precautions","mono":"<ul><li>abrupt diuresis, prolonged therapy, or severe cirrhosis; increased risk for hypokalemia; monitoring recommended<\/li><li>concomitant use with lithium is generally not recommended<\/li><li>cholesterol and triglyceride elevations may occur<\/li><li>electrolyte disturbances, including hyponatremia, hypokalemia, hypochloremic alkalosis, and hypomagnesemia may occur; monitoring recommended<\/li><li>hepatic impairment or progressive liver disease; increased risk of hepatic coma<\/li><li>hyperglycemia may occur; patients with diabetes may require dose adjustments; increased risk for the development of latent diabetes<\/li><li>hyperuricemia may occur; increased risk for gout exacerbations<\/li><li>infants and children; IV use is not generally recommended<\/li><li>postsympathectomy patients; antihypertensive effect may be enhanced<\/li><li>renal disease, severe; increased risk of azotemia<\/li><li>renal impairment; cumulative drug effects may occur<\/li><li>sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma<\/li><li>systemic lupus erythematosus exacerbation or activation has been reported<\/li><li>report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"923284-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Chlorothiazide: C (FDA)<\/li><li>Chlorothiazide: C (AUS)<\/li><\/ul>"},{"id":"923284-s-3-12","title":"Breast Feeding","mono":"<ul><li>Chlorothiazide: AAP: Maternal medication usually compatible with breastfeeding.<\/li><li>Chlorothiazide: Micromedex: Milk effects are possible.<\/li><\/ul>"}]},"4":{"id":"923284-s-4","title":"Drug Interactions","sub":{"1":{"id":"923284-s-4-14","title":"Major","mono":"<ul><li>Acetyldigoxin (established)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Deslanoside (established)<\/li><li>Digitalis (established)<\/li><li>Digitoxin (established)<\/li><li>Digoxin (established)<\/li><li>Dofetilide (probable)<\/li><li>Flecainide (theoretical)<\/li><li>Ketanserin (theoretical)<\/li><li>Lithium (probable)<\/li><li>Metildigoxin (established)<\/li><li>Teriflunomide (probable)<\/li><\/ul>"},"2":{"id":"923284-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Alacepril (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Benazepril (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Calcium (probable)<\/li><li>Captopril (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Cilazapril (probable)<\/li><li>Clonixin (probable)<\/li><li>Delapril (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Enalapril (probable)<\/li><li>Enalaprilat (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Fosinopril (probable)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Imidapril (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Licorice (probable)<\/li><li>Lisinopril (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Moexipril (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Pentopril (probable)<\/li><li>Perindopril (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Quinapril (probable)<\/li><li>Ramipril (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Spirapril (probable)<\/li><li>Sulindac (probable)<\/li><li>Temocapril (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Trandolapril (probable)<\/li><li>Valdecoxib (probable)<\/li><li>Zofenopril (probable)<\/li><\/ul>"}}},"5":{"id":"923284-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Necrotizing vasculitis<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Erythroderma<\/li><li><b>Endocrine metabolic:<\/b>Hypokalemia, Hyponatremia<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia<\/li><li><b>Hepatic:<\/b>Jaundice<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Renal:<\/b>Renal failure<\/li><li><b>Respiratory:<\/b>Pneumonitis, Pulmonary edema, Respiratory distress<\/li><\/ul>"},"6":{"id":"923284-s-6","title":"Drug Name Info","sub":{"0":{"id":"923284-s-6-17","title":"US Trade Names","mono":"<ul><li>Diuril Sodium<\/li><li>Sodium Diuril<\/li><\/ul>"},"2":{"id":"923284-s-6-19","title":"Class","mono":"<ul><li>Cardiovascular Agent<\/li><li>Diuretic<\/li><li>Thiazide<\/li><\/ul>"},"3":{"id":"923284-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923284-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"923284-s-7","title":"Mechanism Of Action","mono":"Chlorothiazide is an antihypertensive and diuretic drug that affects the distal renal tubular mechanism of electrolyte reabsorption. It increases sodium and chloride excretion in approximately equivalent amounts. However, the antihypertensive mechanism of thiazides is still unknown.<br\/>"},"8":{"id":"923284-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"923284-s-8-25","title":"Metabolism","mono":"Not metabolized <br\/>"},"3":{"id":"923284-s-8-26","title":"Excretion","mono":"<ul><li>Renal: rapid excretion, 96% unchanged<\/li><li>Dialyzable: No (hemodialysis)<\/li><\/ul>"},"4":{"id":"923284-s-8-27","title":"Elimination Half Life","mono":"45 to 120 minutes <br\/>"}}},"9":{"id":"923284-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>do not give subQ or IM<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute with 18 mL of Sterile Water for Injection to a final concentration of 28 mg\/mL and use immediately; do not use less than 18 mL of Sterile Water for Injection<\/li><li>may further dilute appropriate dose of the reconstituted solution with dextrose or sodium chloride solutions<\/li><li>give by slow IV injection or by infusion<\/li><li>avoid simultaneous administration with whole blood or its derivatives<\/li><\/ul><\/li><\/ul>"},"10":{"id":"923284-s-10","title":"Monitoring","mono":"<ul><li>reduction in edema may indicate efficacy<\/li><li>serum electrolytes; periodically at appropriate intervals<\/li><li>urine electrolytes; periodically at appropriate intervals<\/li><li>elderly patients: consider renal function<\/li><li>fluid and electrolyte imbalance (confusion, seizures, oliguria, tachycardia, hypotension)<\/li><\/ul>"},"11":{"id":"923284-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Powder for Solution: 0.5 GM<br\/><\/li><li><b>PremierPro RX Chlorothiazide Sodium<\/b><br\/>Intravenous Powder for Solution: 0.5 GM<br\/><\/li><li><b>Sodium Diuril<\/b><br\/>Intravenous Powder for Solution: 0.5 GM<br\/><\/li><\/ul>"},"12":{"id":"923284-s-12","title":"Toxicology","sub":[{"id":"923284-s-12-31","title":"Clinical Effects","mono":"<b>DIURETICS<\/b><br\/>USES: Class of drugs that are primarily used to treat hypertension and congestive heart failure. Potassium sparing diuretics and carbonic anhydrase inhibitors are covered in separate managements. PHARMACOLOGY: Work in a variety of mechanisms including inhibiting sodium and chloride reabsorption in the distal convoluted tubule (thiazides), inhibiting transport of sodium, potassium, and chloride in the thick ascending limb of the loop of henle (loop), and osmotic agents (mannitol). TOXICOLOGY: Produce hypovolemia and electrolyte deficiencies. EPIDEMIOLOGY: Rare overdose which uncommonly results in significant morbidity or death. MILD TO MODERATE TOXICITY: Mild dehydration, tachycardia, dry mucous membranes, headache, muscle cramps, thirst, and brisk diuresis. Large doses of furosemide or ethacrynic acid can cause ototoxicity. SEVERE TOXICITY: Hypotension, hypochloremic metabolic alkalosis, mental status changes, and electrolyte abnormalities (i.e. hypokalemia, hypomagnesemia, hypochloremia, hypocalcemia) are the most common manifestations of severe poisoning. Rarely muscle spasms, tetany, seizures, coma, or dysrhythmias may develop secondary to severe electrolyte abnormalities.  CNS depression has been reported rarely in children with acute ingestion without significant electrolyte abnormalities. ADVERSE EFFECTS: Thiazides are associated with hyperglycemia and hyperlipidemia. Furosemide has been associated with ototoxicity, hyperglycemia, and hypercholesterolemia.  Diuretics have a large number of drug interactions as well. Extravasation of mannitol can cause tissue injury and compartment syndrome.<br\/>"},{"id":"923284-s-12-32","title":"Treatment","mono":"<b>DIURETICS<\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Patients with minor symptoms can be managed with supportive care only.  Oral hydration and oral electrolyte supplementation may be sufficient.  Severe electrolyte disturbances and\/or mental status changes indicate a more severe poisoning. MANAGEMENT OF SEVERE TOXICITY: Severe toxicity is very rare. Treatment should be directed at intravenous correction of volume loss and electrolyte abnormalities.<\/li><li>Decontamination: PREHOSPITAL: Prehospital decontamination is not indicated as toxicity is rare. HOSPITAL: Activated charcoal is rarely  indicated as acute toxicity is rare.<\/li><li>Airway management: Diuretic poisoning should not produce symptoms mandating airway management.<\/li><li>Antidote: There is no specific antidote.<\/li><li>Monitoring of patient: Monitor vital signs and serum electrolytes.  Obtain an ECG in patients with significant electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is not expected to be helpful.<\/li><li>Patient disposition: HOME CRITERIA: Asymptomatic patients with inadvertent ingestion of less than a maximal daily dose can be monitored at home. OBSERVATION CRITERIA: Adults with intentional ingestions or symptomatic children should be referred to a health care facility.  Patients who are asymptomatic after 6 hours can be discharged home. ADMISSION CRITERIA: Patients who have severe electrolyte abnormalities or vital sign abnormalities should be admitted. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing severe poisonings.<\/li><\/ul>"},{"id":"923284-s-12-33","title":"Range of Toxicity","mono":"<b>DIURETICS<\/b><br\/>TOXICITY: Toxic doses are not well established.  Diuresis is expected to result at even therapeutic doses.  Toxicity is most common with chronic dosing and acute toxicity is often related to other factors such as comorbid conditions and access to fluid replacement. THERAPEUTIC DOSE: Furosemide is typically dosed at 20 to 80 mg with repeat doses as necessary in adults; pediatric dose is 1 to 2 mg\/kg orally.  Hydrochlorothiazide is typically dosed at 12.5 to 50 mg daily in adults; pediatric dose is 1 to 3 mg\/kg divided twice daily.<br\/>"}]},"13":{"id":"923284-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause muscle spasm, weakness, diarrhea, nausea, vomiting, photosensitivity, hyperglycemia, vertigo, headache, or transient blurred vision.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the counter, nutritional supplements, vitamins, and herbal drugs).<\/li><li>Avoid concomitant lithium use.<\/li><\/ul>"}}}